Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.
about
Towards tumor immunodiagnosticsCellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of ImmunotherapyTumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerBreast cancer survival among young women: a review of the role of modifiable lifestyle factorsRelevance of tumor-infiltrating lymphocytes in breast cancerCurrent Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerControl of CD8 T-Cell Infiltration into Tumors by Vasculature and MicroenvironmentExercise training and immune crosstalk in breast cancer microenvironment: exploring the paradigms of exercise-induced immune modulation and exercise-induced myokinesBiological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage ResponsPredictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer.The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patientsThe innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients.Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.Dual roles for immune metagenes in breast cancer prognosis and therapy prediction.Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer.The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.Pilot study of p62 DNA vaccine in dogs with mammary tumorsAssessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapyPre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patientsPrognostic and predictive value of PDL1 expression in breast cancer.PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating LymphocytesIdentification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancerImmune profiling in human breast cancer using high-sensitivity detection and analysis techniquesPatterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.Baseline blood immunological profiling differentiates between Her2-breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response.Profiling the immune stromal interface in breast cancer and its potential for clinical impactAssociation of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast CancerAssociation between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study.
P2860
Q26738691-80CEA5D9-BE46-475C-9F9E-386E0A64E4A9Q26745444-08114988-8E21-40B8-8992-84BDEA9D406BQ26745446-CC3BFE59-4FA9-40EE-BA07-DE6C0B37AA46Q26766205-BECBF2BC-65AF-4584-8949-BAF7699A729DQ26795598-6D4187AE-EA95-410F-9807-471A0C8CA64FQ26798074-AE10BFBD-218B-4470-BB0B-5EB9FFC1248DQ26799117-F18CFA0A-1FD1-4605-B247-54B8E0EA0BD9Q26865918-ECF2D80E-0107-4285-A229-345BAB452C66Q27311085-FD511775-E0F0-41BD-B015-A8B2FF18E8CCQ30253017-9C273F0F-7058-4F12-A526-A69DB3D0AC03Q33441772-F22581F4-E3A4-4886-B6E2-4E02AB4957C7Q33584033-46DE1EB7-7299-4F8F-B7A2-64192B37A93AQ33611598-D62EC4EE-EA0D-46C0-97DA-667C6255A498Q33613591-AF352056-AD12-4F36-80E1-5DF8D82728FCQ33660069-1BA376E4-931E-4E6D-850A-8369443B284AQ33769821-F6595D6B-D824-4A76-AEDC-8396FC55E4DEQ33960985-1C7E54EE-2771-4CCA-8EC2-BC02FF5888E0Q34172008-F8507120-75C7-42BD-9A73-3C4565686DCBQ34325790-6625FEC2-207B-4EAD-B85B-BF0519BADF10Q34417532-30461BE2-12C9-4FD4-99B2-6B816A8D7547Q34547261-7B2DF5C1-8FF2-4AE5-92F8-CEF23DBFBDB0Q34558758-BD8BA710-655C-471C-B03E-B1DEA3C890A1Q34616067-CA9F865F-276B-4E6D-9FA5-09788F3C2090Q34690824-6D2A2D5B-3F73-44E0-91CB-B13B7F03612FQ35000651-DA3FDE84-D90E-46E3-9129-2410304D0DF4Q35102480-D1AEF870-4576-473E-A44D-A689C63984BBQ35149622-7920E447-C3CB-42E2-8DAB-E87587195C39Q35218520-7FFB56CA-4F86-41B3-961F-3A592845A780Q35595696-44D4B4F4-22C4-410E-B0CF-4EAEF57070DFQ35741710-47176019-2792-4AAE-A864-B5A5E0A4EAC2Q35955369-5124128C-EC6E-42FF-8E0D-0A2947AAF0FEQ35958861-C06CF6C2-574E-4286-892C-3EE864036895Q35992815-A277597E-20B1-4BB7-85CB-912D3D3B1A87Q36108008-6CA76246-450D-4512-BAA3-E5CC3A72B737Q36222126-A9BF7B6D-14CC-4E87-97BE-D37E1FFFA3E0Q36231343-73CC374A-E273-4CB0-BA07-1E12A672BEDAQ36307206-6F9E355A-52C7-4D48-BCCB-D3D865CB1E2BQ36449295-960870A2-0C4F-41F0-8D27-9B91DB4B53A9Q36463604-D0E73644-0242-464F-A713-0C390992A76BQ36490577-B1CC1FF4-C372-4085-904E-430014B3EFE9
P2860
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Tumor-infiltrating lymphocytes ...... ceptor-negative breast cancer.
@ast
Tumor-infiltrating lymphocytes ...... ceptor-negative breast cancer.
@en
type
label
Tumor-infiltrating lymphocytes ...... ceptor-negative breast cancer.
@ast
Tumor-infiltrating lymphocytes ...... ceptor-negative breast cancer.
@en
prefLabel
Tumor-infiltrating lymphocytes ...... ceptor-negative breast cancer.
@ast
Tumor-infiltrating lymphocytes ...... ceptor-negative breast cancer.
@en
P2093
P2860
P356
P1476
Tumor-infiltrating lymphocytes ...... eceptor-negative breast cancer
@en
P2093
Katy Milne
Nicol Macpherson
Pauline T Truong
Peter H Watson
P2860
P2888
P356
10.1186/BCR3072
P577
2011-12-08T00:00:00Z
P5875
P6179
1028184592